Cargando…

Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide

Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal...

Descripción completa

Detalles Bibliográficos
Autores principales: Schafranski, Marcelo Derbli, Campanari, Giuliano Doretto
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003994/
https://www.ncbi.nlm.nih.gov/pubmed/21188210
http://dx.doi.org/10.1155/2010/951850
_version_ 1782193938030919680
author Schafranski, Marcelo Derbli
Campanari, Giuliano Doretto
author_facet Schafranski, Marcelo Derbli
Campanari, Giuliano Doretto
author_sort Schafranski, Marcelo Derbli
collection PubMed
description Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal anti-inflammatory drugs, potent immunosuppressants are sometimes required for the management of the refractory situations. Here we describe a case of a 32-year-old Caucasian female patient with history of idiopathic cutaneous deep vasculitis unresponsive to methotrexate, dapsone, and cyclophosphamide who was effectively treated with infliximab.
format Text
id pubmed-3003994
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30039942010-12-23 Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide Schafranski, Marcelo Derbli Campanari, Giuliano Doretto Int J Vasc Med Case Report Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal anti-inflammatory drugs, potent immunosuppressants are sometimes required for the management of the refractory situations. Here we describe a case of a 32-year-old Caucasian female patient with history of idiopathic cutaneous deep vasculitis unresponsive to methotrexate, dapsone, and cyclophosphamide who was effectively treated with infliximab. Hindawi Publishing Corporation 2010 2010-06-27 /pmc/articles/PMC3003994/ /pubmed/21188210 http://dx.doi.org/10.1155/2010/951850 Text en Copyright © 2010 M. D. Schafranski and G. D. Campanari. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Schafranski, Marcelo Derbli
Campanari, Giuliano Doretto
Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
title Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
title_full Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
title_fullStr Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
title_full_unstemmed Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
title_short Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
title_sort infliximab for idiopathic deep cutaneous vasculitis refractory to cyclophosphamide
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003994/
https://www.ncbi.nlm.nih.gov/pubmed/21188210
http://dx.doi.org/10.1155/2010/951850
work_keys_str_mv AT schafranskimarceloderbli infliximabforidiopathicdeepcutaneousvasculitisrefractorytocyclophosphamide
AT campanarigiulianodoretto infliximabforidiopathicdeepcutaneousvasculitisrefractorytocyclophosphamide